2,5-Dimethoxy-4-trifluoromethylamphetamine

2,5-Dimethoxy-4-trifluoromethylamphetamine
Clinical data
Other names2,5-Dimethoxy-4-trifluoromethylamphetamine; 4-Trifluoromethyl-2,5-dimethoxyamphetamine; DOTFM; 3C-TFM
Routes of
administration
Oral[1][2]
Legal status
Legal status
Pharmacokinetic data
Duration of actionUnknown[1][2]
Identifiers
IUPAC name
  • (RS)-1-[2,5-Dimethoxy-4-(trifluoromethyl)phenyl]propan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H16F3NO2
Molar mass263.260 g·mol−1
3D model (JSmol)
SMILES
  • FC(F)(F)c1cc(OC)c(cc1OC)CC(N)C
InChI
  • InChI=1S/C12H16F3NO2/c1-7(16)4-8-5-11(18-3)9(12(13,14)15)6-10(8)17-2/h5-7H,4,16H2,1-3H3 Y
  • Key:WPGOTSORDNBMHP-UHFFFAOYSA-N Y
  (verify)

2,5-Dimethoxy-4-trifluoromethylamphetamine (DOTFM) is a psychedelic drug of the phenethylamine, amphetamine, and DOx (where 'x' indicates a 4-substitution on the phenyl group of 2,5-dimethoxyamphetamine) families. It was first synthesized in 1994 by a team at Purdue University led by David E. Nichols.[3] DOTFM is the α-methylated analogue of 2C-TFM. It is the most potent DOx psychedelic.[1][2]

  1. ^ a b c Cite error: The named reference Trachsel2012 was invoked but never defined (see the help page).
  2. ^ a b c Cite error: The named reference TrachselLehmannEnzensperger2013 was invoked but never defined (see the help page).
  3. ^ Nichols DE, Frescas S, Marona-Lewicka D, Huang X, Roth BL, Gudelsky GA, et al. (December 1994). "1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist". Journal of Medicinal Chemistry. 37 (25): 4346–4351. doi:10.1021/jm00051a011. PMID 7996545.